BI Aims To ‘Own’ Indian Lung Cancer Space As Afatinib Debuts
This article was originally published in PharmAsia News
"We want to own the lung cancer therapy space" is how Boehringer Ingelheim (BI) India's managing director Sharad Tyagi refers to the family-owned German multinational's ambitions in the segment following the introduction of afatinib, its first oncology product on the Indian market.
You may also be interested in...
Pfizer’s Vizimpro has been endorsed by an expert panel in India, paving the way for its potential introduction on the market, where other EGFR inhibitors including AstraZeneca’s Tagrisso have a head start.
Ex-WHO executive and co-chair of the Asia Pacific Immunization Coalition, Tikki Pangestu, outlined at a recent briefing why he believes herd immunity for COVID-19 will not be achievable against the backdrop of the global spread of the highly contagious Delta variant. Facets of vaccine hesitancy and the complexity of vaccine manufacturing were among the other issues discussed by experts.
The availability later this month of Hetero's biosimilar tocilizumab, ostensibly a less pricey product, could place India in a relatively better situation to cope with any demand spurt should another wave of COVID-19 strike. Innovator product Actemra is expected to be in short supply, going by current trends, given the unprecedented worldwide demand.